122875-03-0

Upstream product

• 104174-43-8 4-(3-methoxyphenyl)butan-1-ol 
• 385810-94-6 4-(3-methoxyphenyl)-1-butyl methanesulfonate 
• 24165-65-9 1-(3-methoxyphenyl)but-3-en-1-ol 
• 591-31-1 3-methoxy-benzaldehyde 
• 107318-70-7 3-(3-methoxyphenyl)propyl 4-methylbenzenesulfonate 
• 7743-29-5 [3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propyl]-triphenyl-phosphonium bromide 
• 54981-94-1 2-[4-(3-Methoxy-phenyl)-butyl]-isoindole-1,3-dione 
• 91152-85-1 3-(3'-methoxyphenyl)-1-butyronitrile 

Downstream Products

• 77515-67-4 1-methoxy-5-(4'-aminobutyl)cyclohexa-1,3-diene 

Relevant academic research and scientific papers

Heterocyclization involving benzylic C(sp3)-H functionalization enabled by visible light photoredox catalysis

A general and efficient method for heterocyclization involving benzylic C(sp3)-H functionalization enabled by visible light photoredox catalysis to access a wide range of structurally diverse oxygen as well as nitrogen heterocycles up to a gram scale is reported. The potential application of this new methodology is demonstrated by the total synthesis of (-)-codonopsinine and (+)-centrolobine. Herein it is proposed that selectfluor, unlike a fluorinating reagent, acts as an oxidative quencher and a hydrogen radical acceptor.

1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy

The invention concerns 3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives of general formula (I), wherein: R1 and R2, identical or different, represent a branched or linear C1-C7 alkyl or alkenyl radical, a C1/s

Synthesis and pharmacological characterization of novel 6-fluorochroman derivatives as potential 5-HT(1A) receptor antagonists

A series of novel 6-fluorochroman derivatives was prepared and evaluated as antagonists for the 5-HT(1A) receptor. N-2-[[(6-Fluorochroman-8- yl)oxy]ethyl]-4-(4-methoxyphenyl)butylamine (3; J. Med. Chem. 1997, 40, 1252- 1257) was chosen as a lead, and structural modifications were done on the aliphatic portion of the chroman ring, the tether linking the middle amine and the terminal aromatic ring, the aromatic ring, and lastly the amine. Radioligand binding assays proved that the majority of the novel compounds behaved as good to excellent ligands at the 5-HT(1A) receptor, some of which were selective with respect to α1-adrenergic and D2-dopaminergic receptors. The antagonist activity of the compounds was assessed in the forskolinstimulated adenylate cyclase assays in CHO cells expressing the human 5-HT(1A) receptors. Among the modifications attempted, introduction of an oxo or an optically active hydroxy moiety at the chroman C-4 position was effective in ameliorating the receptor selectivity. Six analogues were selected through the in vitro screens and further evaluated for their in vivo activities. A 4-oxochroman derivative (31n), having a terminal 1,3- benzodioxole ring, demonstrated antagonist activities toward 8-OH-DPAT- induced behavioral and electrophysiological responses in rats.

Studies on the Synthesis of 1-Azaspiroundecanes Related to Histrionicotoxin

3-Methoxybenzaldehyde was converted into 4-(3-methoxyphenyl)butylamine (4), and the derived hydrochloride was reduced with Li/NH3/EtOH to give the spirocyclic keto amine 6.The reduction of 6 and urethane derivatives 13 and 14 to give the corresponding cis and trans alcohols 9/10, 15/16, and 17/18 was studied.The keto amine 6 upon attempted ketalization underwent rearrangement to give the α,β-unsaturated imine 11.Treatment of 6 with N-chlorosuccinimide, followed by DBU, gave the aziridine 21.The amide 25 was converted derectly into 1-azaspiroundecane-2,8-dione (24) by Birch reduction and acid hydrolysis.The dione 24 underwent stereospecific reduction with LS-Selectride to give the cis alcohol 30.